Role
10%+ Owner
Signature
Wellington Biomedical Innovation Master Investors (Cayman) II L.P. By: Wellington Management Company LLP, as Investment Adviser /s/ Peter McIsaac, Title: Authorized Person
Issuer symbol
BOLD
Transactions as of
02 Apr 2024
Net transactions value
$0
Form type
4
Filing time
02 Apr 2024, 20:42:06 UTC
Previous filing
27 Mar 2024
Next filing
18 Jul 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction BOLD Common Stock Conversion of derivative security +189,933 189,933 02 Apr 2024 Direct F1
transaction BOLD Common Stock Conversion of derivative security +366,300 +193% 556,233 02 Apr 2024 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction BOLD Series B Preferred Stock Conversion of derivative security $0 -3,703,704 -100% $0.000000* 0 02 Apr 2024 Common Stock 189,933 Direct F1
transaction BOLD Series C Preferred Stock Conversion of derivative security $0 -7,142,857 -100% $0.000000* 0 02 Apr 2024 Common Stock 366,300 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 On April 2, 2024, the Series B Preferred Stock automatically converted into Common Stock on a 19.5-for-1 basis without payment of further consideration upon the closing of the initial public offering of the Issuer's common stock. The Series B Preferred Stock had no expiration date.
F2 On April 2, 2024, the Series C Preferred Stock automatically converted into Common Stock on a 19.5-for-1 basis without payment of further consideration upon the closing of the initial public offering of the Issuer's common stock. The Series C Preferred Stock had no expiration date.